Nanobiotix reports 41.7% response rate in Phase 1 trial of NBTXR3 combination for resistant melanoma

• Nanobiotix announced final Phase 1 results showing acceptable safety and early antitumor activity for JNJ-1900 (NBTXR3) in treatment-resistant advanced melanoma.
• The 24-patient study tested the treatment with radiotherapy followed by immune checkpoint therapy; tumor responses occurred in injected and non-injected lesions.
• Results were presented at the European Society for Medical Oncology congress in Madrid on Oct. 24, 2026.
• The preliminary, single-arm findings support further evaluation in larger randomized trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006796), on October 26, 2026, and is solely responsible for the information contained therein.